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Volume 57, Number 5S Abstracts 25Sincluding CIA length (>50mm) and diameter of the CIA
bifurcation (>16mm) and IIA (4-9mm). A right IIA
bypass was performed in a ﬁrst stage via small ﬂank incision.
For the second stage, EVAR was performed using bilateral
percutaneous femoral approach. After systemic hepariniza-
tion, a 12Fr Ansel sheath (Cook Inc., Bloomington IN)
was introduced via the right and IBD via the left femoral
approach. A guidewire was advanced via the IBD pre-
loaded catheter and snared, establishing femoral-femoral
access. The IBD was partially deployed up to the side
branch, which was opened 1-cm proximal to the CIA bifur-
cation. The 12 Fr sheath was advanced into the side
branch, followed by selective catheterization the IIA and
deployment of a 9  60 mm self-expandable stent-graft
into the IIA. The IBD was deployed into the left external
iliac artery (EIA) and kissing balloon angioplasty was per-
formed. The repair was completed by deployment of
a Cook Zenith (Bloomington IN) bifurcated stent-graft
and iliac limb extensions to connect the IBD to the left
contra-lateral gate and extend the repair to the right EIA.
Completion angiography and CTA revealed widely patency
stent-grafts with no endoleak. In conclusion, IBDs have
expanded the indications of EVAR in patients with bilateral
CIA aneurysms. The technique can be performed using
a total percutaneous approach and has the potential to
reduce rates of pelvic ischemic complications.
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Objectives: With over a decade of use of endovascular
aneurysm repair (EVAR) we have seen a rise in the number
of failing endografts. In 2007 we previously reported 41
explants and sought to re-examine our outcomes.
Methods: A retrospective analysis of EVARs requiring
late explant was performed using a database. The type of
graft, duration of implant, reason for removal, operative
technique, mortality and length of stay were reviewed.
Results: During 1999-2012, 100 patients required
explant, of which 60 were placed at an outside institution
(Table). Twenty-seven were performed in the last two years.
Ninety-one were male with an average age of 75 years
(range, 50-93 years). Grafts were excised after a median of
41 months (range, 1-144 months). Average length of stay
was 15 days (range, 1-56 days). 30 day mortality was 17%.
Elective mortality was 9.9%. There was no difference in
approach (56 retroperitoneal, 44 midline). 82% patients
had one or more endoleaks (type I, 40; II, 30; III, 22; endo-
tension, six). Migration (15), rupture (nine), aortoenteric
ﬁstula (ﬁve), infection (13), limb thrombosis (three) and
claudication (one) were also factors. Repairs were 18 tube,
66 aortoiliac, eight aorto-femoral, and seven axillo-femoral.
Twenty-two patients had partial graft excision.Conclusions: An increasing number of endografts are
being referred for removal. The overall mortality is slightly
improved to 17% from 19% in our original series despite
increased elective mortality to 9.9% from 3.3%.
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Objectives: Patients with vascular Ehlers-Danlos syn-
drome (vEDS) often present with spontaneous arterial
dissection or rupture. Mutations in the COL3A1 gene
that encodes type III collagen include missense mutations
(MIS) and haploinsufﬁciency (HI) mutations. The aim is
to describe the outcomes of vEDS patients based on
genotype.
